All
Bunick Busts 10 Myths On Boxed Warnings
There is a lot of conversation drumming around the boxed warnings for newer JAK inhibitors, and fact versus fiction was discussed at Fall Clinical.
QUIZ: Which of the Following Conditions is NOT a Mimicker of Melasma?
Susan Taylor, MD, walked Fall Clinical attendees through an in-depth hyperpigmentation session that included melasma and its mimickers.
Joslyn Kirby, MD, Shares OTC Product Benefits and HS Procedural Pearls
Kirby presented at both Fall Clinical and the Inflammatory Disease Summit in Las Vegas.
Considerations to Manage Different Types of Acne Scars
Sandra Lee, MD, and other top acne experts took the stage to debate cases and treatments.
Photoprotection Education to Share With Patients
Primary and secondary melanoma prevention factors are necessary to reduce patients’ melanoma risk.
Editorial Advisory Board Insights for Eczema Awareness Month: Renata Block, MMS, PA-C
Renata Block, MMS, PA-C, shares her atopic dermatitis insights.
STI Trends and a Dermatologist's Role With Ted Rosen, MD
The latest CDC data shows an uptick in syphilis, which can lead to a rare form of alopecia or a presentation of psoriasis.
2023 Fall Clinical Recap: Day 3
Catch up on coverage from the third day of the 2023 Fall Clinical Dermatology Conference.
Addressing Healthcare Disparities and Improving Care for People with Skin of Color With Patient Navigators
Although still in its early stages, the program showcases the potential value of tangible interactions between dedicated navigators and patients in enhancing support and continuity of care.
Derm In The News: October 15-21
Keep up with the latest headlines in dermatology from the past week, including the creation of a dermatology outreach organization centered in Detroit, a tropical skin disease endemic in parts of the US, and more.
Adding Cabtreo to the Acne Vulgaris Tool Box
Christopher Bunick, MD, PhD, reviews Cabtreo’s recent FDA approval and what the new triple-combination gel means for acne patients.
APG777: A Promising Breakthrough in IL-13 Targeted Therapy
The pharmacokinetic profile of APG777, characterized by an extended half-life, increased exposure, and reduced clearance compared to lebrikizumab, is promising for patients with IL-13-driven diseases.
40-GEP Identifies Patients Who Benefit Most From Adjuvant Radiation Therapy With Improved Metastasis-Free Survival of cSCC
The goal of Arron et al’s study was to determine if the 40-GEP test could identify high-risk cSCC patients who would benefit from ART in controlling metastatic disease progression.
Enhancing Skin Health With Macrocystis Pyrifera Ferment-Containing Creams
The positive outcomes observed in these cases underscore the potential for these products to revolutionize the way dermatology clinicians address visible signs of facial aging.
Overcoming Early Career Conundrums and Burnout With Muneeb Shah, DO
Shah is presenting alongside a panel of leading experts at Fall Clinical 2023.
A Deep Dive Into the Chronic Spontaneous Urticaria Armamentarium
Dawn Merritt, DO, and Mark Lebwohl, MD, took the stage to explain the history of CSU, the prevalence of testing and food avoidance, approved treatments, and monitoring treatment improvement for the condition.
2023 Fall Clinical Recap: Day 2
Catch up on coverage from the second day of the 2023 Fall Clinical Dermatology Conference.
Camp Wonder: Supporting Children With Life-Threatening Skin Diseases
Francesca Tenconi, president and CEO of Children’s Skin Disease Foundation and Camp Wonder, presented at Fall Clinical 2023 about the challenges of chronic skin conditions in children.
IDP-126 Approved by FDA for Treatment of Acne
The US Food and Drug Administration has approved IDP-126 gel for patients with acne.
FDA Issues Complete Response Letter for Dupilumab sBLA for Chronic Spontaneous Urticaria
The CRL states that additional efficacy data is needed in order to support approval.
2023 Inflammatory Disease Summit Recap
If you weren’t able to attend the 2023 Inflammatory Disease Summit or want to review our latest coverage and interviews, our full recap has you covered.
Breaking Down JAKs and TYKs
Kristine Kucera, PA-C, gave an in-depth overview of the JAK-STAT pathway at the 2023 Inflammatory Disease Summit.
Patient Perspective: Solutions for Relief After Years of Pain and Itch
Lisa Sanglay, FNP, and Lauren Miller, PA-C, interviewed a patient at IDS 2023 who used to have debilitating atopic dermatitis before seeing Sanglay for help and who prescribed upadacitinib.
Dermavant Shares Positive Phase 4 Tapinarof Data For Intertriginous Plaque Psoriasis
82.8% of adult patients with iPsO achieved an IGA score of 0 or 1 indicative of complete or almost complete lesion clearance.
Utilizing Biologics in the Management of Moderate to Severe Atopic Dermatitis
April Armstrong, MD, MPH, and Peter Lio, MD, explained the science behind how AD impacts quality of life and biologics on the market to enhance treatment plans.
80% of Patients With AD Demonstrated Sustained Skin Clearance With Lebrikizumab in 2-Year Data
Skin clearance, itch relief, and reduced severity of atopic dermatitis were sustained with monthly maintenance dosing.
Reviewing IDS 2023 and Psoriasis Clinical Cases With Tristan Hasbargen, PA-C
Hasbargen presented clinical cases alongside James Del Rosso, DO, at IDS 2023.
Data From Cohort of Janssen’s VISIBLE Trial Reveals Significant Skin Clearance in PsO Patients With Skin of Color
Topline results from the phase 3b trial revealed significant improvements in patients with skin of color whose psoriasis was treated with guselkumab.
Shawn Kwatra, MD: Managing Prurigo Nodularis With Biologics
Kwatra reviewed skin lesions in PN and important treatment considerations for patients at Fall Clinical.
2023 Fall Clinical Recap: Day 1
Catch up on coverage from the first day of the 2023 Fall Clinical Dermatology Conference and the Inflammatory Disease Summit.